$VISM
VISIUM TECHNOLOGIES, INC.

2023 Q1 Form 10-Q Financial Statement

#000165495423001733 Filed on February 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $568.0K $533.9K $1.265M
YoY Change -56.2% -57.78% 650.45%
% of Gross Profit
Research & Development $73.76K $47.06K $196.3K
YoY Change -5.79% -76.03%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $641.7K $581.0K $1.351M
YoY Change -53.33% -56.98% 652.35%
Operating Profit -$641.7K -$581.0K -$1.351M
YoY Change -53.33% -56.98% 652.35%
Interest Expense $20.27K $37.20K -$445.3K
YoY Change -115.67% -108.35% -38.4%
% of Operating Profit
Other Income/Expense, Net -$90.35K -$140.6K $60.04K
YoY Change -30.12% -334.12% -106.08%
Pretax Income -$732.1K -$721.5K -$3.106M
YoY Change -51.33% -76.77% 165.99%
Income Tax
% Of Pretax Income
Net Earnings -$732.1K -$721.5K -$1.290M
YoY Change -51.33% -44.09% 10.5%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.16 -$0.22 -$880.20
COMMON SHARES
Basic Shares Outstanding 4.335M shares 3.170M shares
Diluted Shares Outstanding 3.272M shares 432.5K shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.75K $31.39K $361.6K
YoY Change -86.74% -91.32% 616.1%
Cash & Equivalents $46.75K $31.39K $361.6K
Short-Term Investments
Other Short-Term Assets $17.50K $35.00K $20.42K
YoY Change 499.32% 71.4%
Inventory
Prepaid Expenses $17.50K $35.00K $20.42K
Receivables
Other Receivables
Total Short-Term Assets $64.25K $66.39K $382.0K
YoY Change -81.93% -82.62% 656.54%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $64.25K $66.39K $382.0K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $64.25K $66.39K $382.0K
YoY Change -81.93% -82.62% 656.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $661.2K $643.4K $516.2K
YoY Change 43.45% 24.65%
Accrued Expenses $1.625M $1.462M $1.051M
YoY Change 52.4% 39.06% -30.06%
Deferred Revenue
YoY Change
Short-Term Debt $1.775M $1.763M $670.4K
YoY Change 38.35% 163.05% -50.07%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.316M $4.064M $2.366M
YoY Change 43.16% 71.76% -43.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.316M $4.064M $2.366M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $4.316M $4.064M $2.366M
YoY Change 43.16% 71.76% -43.96%
SHAREHOLDERS EQUITY
Retained Earnings -$59.05M -$58.32M -$54.47M
YoY Change 5.49% 7.06%
Common Stock $559.00 $398.00 $362.0K
YoY Change -99.85% -99.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.251M -$3.997M -$1.984M
YoY Change
Total Liabilities & Shareholders Equity $64.25K $66.39K $382.0K
YoY Change -81.93% -82.62% 656.54%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2021 Q4
OPERATING ACTIVITIES
Net Income -$732.1K -$721.5K -$1.290M
YoY Change -51.33% -44.09% 10.5%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$174.6K -$110.7K -$413.2K
YoY Change -78.68% -73.21% 164.71%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.0K 119.5K -225.0K
YoY Change -76.54% -153.11% -209.94%
NET CHANGE
Cash From Operating Activities -174.6K -110.7K -413.2K
Cash From Investing Activities
Cash From Financing Activities 190.0K 119.5K -225.0K
Net Change In Cash 15.36K 8.820K -638.2K
YoY Change -271.43% -101.38% -1414.27%
FREE CASH FLOW
Cash From Operating Activities -$174.6K -$110.7K -$413.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001082733
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q3 vism Common Stock Shares Authorized To Be Issued
CommonStockSharesAuthorizedToBeIssued
10000000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-25753
dei Entity Registrant Name
EntityRegistrantName
VISIUM TECHNOLOGIES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0449667
dei Entity Address Address Line1
EntityAddressAddressLine1
4094 MAJESTIC LANE
dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 360
dei Entity Address City Or Town
EntityAddressCityOrTown
FAIRFAX
dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
22033
dei City Area Code
CityAreaCode
703
dei Local Phone Number
LocalPhoneNumber
273-0383
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4334654 shares
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
412944 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5486121 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3986103 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2903804 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2896385 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
398 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
288 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
53749386 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56558552 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-2793558 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136990 usd
CY2022Q4 us-gaap Revenues
Revenues
0 usd
CY2021Q4 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2022Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
533892 usd
CY2021Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1264592 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
893581 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2464629 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47060 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85912 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101952 usd
CY2021Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-504925 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
196325 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
580952 usd
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
1350504 usd
us-gaap Operating Expenses
OperatingExpenses
995533 usd
us-gaap Operating Expenses
OperatingExpenses
2660954 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-580952 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
37199 usd
CY2021Q4 us-gaap Interest Expense
InterestExpense
15211 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1350504 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-995533 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2660954 usd
CY2022Q4 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-45233 usd
CY2021Q4 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
75253 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-33862 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
56345 usd
us-gaap Interest Expense
InterestExpense
166940 usd
CY2022Q4 vism Derivative Liability Expense
DerivativeLiabilityExpense
-58139 usd
CY2021Q4 vism Derivative Liability Expense
DerivativeLiabilityExpense
0 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
-58139 usd
us-gaap Interest Expense
InterestExpense
501675 usd
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-140571 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
0 usd
CY2022Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
60042 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-763866 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-445330 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-721523 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1290462 usd
us-gaap Net Income Loss
NetIncomeLoss
-1759399 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
225000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
67500 usd
us-gaap Net Income Loss
NetIncomeLoss
-3106284 usd
CY2021Q4 vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-2.98
vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.57
vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-10.46
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3271675 shares
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
432481 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3085138 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
297026 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-3601480 usd
CY2022Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3100 usd
CY2022Q4 vism Shares Issued As Compensation To Employees Amount
SharesIssuedAsCompensationToEmployeesAmount
72850 usd
CY2022Q4 vism Shares Issued As Compensation To Directors And Officers Amount
SharesIssuedAsCompensationToDirectorsAndOfficersAmount
172604 usd
CY2022Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
77049 usd
CY2022Q4 vism Shares Issued For Exercise Of Warrants Amount
SharesIssuedForExerciseOfWarrantsAmount
0 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-721523 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3997400 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-2793558 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
18873 usd
vism Shares Issued As Compensation To Employees Amount
SharesIssuedAsCompensationToEmployeesAmount
72850 usd
vism Shares Issued As Compensation To Directors And Officers Amount
SharesIssuedAsCompensationToDirectorsAndOfficersAmount
199813 usd
vism Warrants Issued On Extinguishment Of Debt
WarrantsIssuedOnExtinguishmentOfDebt
186972 usd
vism Stockissuedduringperiodsharescshares Issued For Conversion Of Notes Payable And Accrued Interest Amountonversionofconvertiblesecurities
StockissuedduringperiodsharescsharesIssuedForConversionOfNotesPayableAndAccruedInterestAmountonversionofconvertiblesecurities
77049 usd
vism Shares Issued For Exercise Of Warrants Amount
SharesIssuedForExerciseOfWarrantsAmount
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-1759399 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-1609690 usd
CY2021Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
402583 usd
CY2021Q4 vism Shares Issued As Compensation Amount
SharesIssuedAsCompensationAmount
473000 usd
CY2021Q4 vism Amortization Of Deferred Compensation
AmortizationOfDeferredCompensation
40524 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1290462 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-1984045 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-2837187 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
729331 usd
vism Shares Issued As Compensation Amount
SharesIssuedAsCompensationAmount
818000 usd
vism Shares Issued For Conversion Of Notes Payable And Accrued Interest Amount
SharesIssuedForConversionOfNotesPayableAndAccruedInterestAmount
831047 usd
vism Shares Issued Pursuant To Sale Of Common Stock Amount
SharesIssuedPursuantToSaleOfCommonStockAmount
1500000 usd
vism Shares Issued For Exercise Of Warrants Amount
SharesIssuedForExerciseOfWarrantsAmount
0 usd
vism Amortization Of Deferred Compensation
AmortizationOfDeferredCompensation
81048 usd
us-gaap Net Income Loss
NetIncomeLoss
-3106284 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-1984045 usd
us-gaap Net Income Loss
NetIncomeLoss
-1759399 usd
us-gaap Net Income Loss
NetIncomeLoss
-3106284 usd
us-gaap Share Based Compensation
ShareBasedCompensation
291536 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1547332 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
94956 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
410922 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
-58139 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-33862 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
56345 usd
us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
0 usd
us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
81048 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-504925 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
50467 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
90353 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
35000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
172500 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1160000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-105599 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
236394 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-35000 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-71981 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-64368 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
410434 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136990 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
115000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
105000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
10000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-278099 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-923606 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1500000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125166 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31391 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
361560 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
22011 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
vism Issuance Of Common Stock For Conversion Of Notes Payable And Accrued Interest
IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterest
77049 usd
vism Issuance Of Common Stock For Conversion Of Notes Payable And Accrued Interest
IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterest
831047 usd
vism Warrants Issued On Extinguishment Of Debt
WarrantsIssuedOnExtinguishmentOfDebt
186972 usd
vism Warrants Issued On Extinguishment Of Debt
WarrantsIssuedOnExtinguishmentOfDebt
0 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 vism Common Stock Shares Authorized To Be Issued
CommonStockSharesAuthorizedToBeIssued
10000000000 shares
us-gaap Profit Loss
ProfitLoss
-1759399 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-278099 usd
CY2022Q4 vism Working Capital Deficit
WorkingCapitalDeficit
-3997400 usd
us-gaap Fiscal Period
FiscalPeriod
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fiscal year ends on June 30. References to fiscal year 2023, for example, refer to the fiscal year ending June 30, 2023.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reporting amounts of revenues and expenses during the reported period. Actual results will differ from those estimates. Included in these estimates are assumptions used in Cox, Ross &amp; Rubinstein Binomial Tree stock-based compensation valuation methods, such as expected volatility, risk-free interest rate, and expected dividend rate and in the valuation allowance of deferred tax assets and derivative liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The COVID-19 pandemic and related developments have created and may continue to create significant uncertainty in global financial markets, which may decrease technology spending, depress demand for our products and harm our business and results of operations. As of the date of issuance of the financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates or judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, which could be recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our financial statements.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is subject to a concentration of credit risk from cash.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s cash account is held at a financial institution and is insured by the Federal Deposit Insurance Corporation, or FDIC, up to $250,000. The Company did not have cash on deposit in excess of such limit on December 31, 2022 and June 30, 2022.</p>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
127298 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3085138 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2424513 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4382044 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
71045 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
11348 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
11348 shares
vism Incremental Common Shares Attributable To Common Stock Option
IncrementalCommonSharesAttributableToCommonStockOption
2222 shares
vism Incremental Common Shares Attributable To Common Stock Option
IncrementalCommonSharesAttributableToCommonStockOption
5926 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
69049 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
5049 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
7549801 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2517881 shares
vism Annually Prepaid License Fee
AnnuallyPrepaidLicenseFee
70000 usd
us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
35000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.02
vism Convertible Notes Payables
ConvertibleNotesPayables
-33862 usd
vism Convertible Notes Payables
ConvertibleNotesPayables
56345 usd
CY2022Q4 vism Derivative Liabilities Fair Value Assumptions Market Price
DerivativeLiabilitiesFairValueAssumptionsMarketPrice
0.081
CY2021Q4 vism Derivative Liabilities Fair Value Assumptions Market Price
DerivativeLiabilitiesFairValueAssumptionsMarketPrice
8.10
vism Derivative Liabilities Fair Value Assumptions Expected Dividend Rate
DerivativeLiabilitiesFairValueAssumptionsExpectedDividendRate
0 pure
vism Derivative Liabilities Fair Value Assumptions Expected Dividend Rate
DerivativeLiabilitiesFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
35297 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
58139 usd
vism Loss On Change In Fair Value Of Derivative Liabilities
LossOnChangeInFairValueOfDerivativeLiabilities
33862 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
127298 usd
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
404712 usd
vism Payments Of Accrued Interest
PaymentsOfAccruedInterest
71980 usd
vism Conversion Of Accrued Interest
ConversionOfAccruedInterest
-39599 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
437093 usd
CY2022Q4 vism Convertible Notes Payable1
ConvertibleNotesPayable1
1558481 usd
CY2022Q2 vism Convertible Notes Payable1
ConvertibleNotesPayable1
1487431 usd
CY2022Q2 vism Convertible Notes Payable To Related Parties Current
ConvertibleNotesPayableToRelatedPartiesCurrent
1074487 usd
CY2022Q4 vism Discount On Convertible Notes Payable
DiscountOnConvertibleNotesPayable
0 usd
CY2022Q2 vism Discount On Convertible Notes Payable
DiscountOnConvertibleNotesPayable
-412944 usd
CY2022Q4 vism Convertible Notes Payable To Related Parties Current
ConvertibleNotesPayableToRelatedPartiesCurrent
1558481 usd
CY2022Q4 vism Convertible Notes Payable2
ConvertibleNotesPayable2
1558481 usd
CY2022Q2 vism Convertible Notes Payable2
ConvertibleNotesPayable2
1074487 usd
vism Scheduleofconvertible Notes Payabletabletextblock
ScheduleofconvertibleNotesPayabletabletextblock
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible payable at June 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,487,431</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible notes issued during the six months ended December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">105,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Conversion of convertible notes payable into common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(33,950 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible payable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,558,481</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q2 vism Convertibles Notes Payable
ConvertiblesNotesPayable
1487431 usd
vism Convertible Notes Issued55
ConvertibleNotesIssued55
105000 usd
vism Conversion Of Convertible Notes Payable Into Common Stock
ConversionOfConvertibleNotesPayableIntoCommonStock
-33950 usd
CY2022Q4 vism Convertibles Notes Payable
ConvertiblesNotesPayable
1558481 usd
vism Value Of Warrants Issued
ValueOfWarrantsIssued
186972 usd
vism Write Off Of Unamortized Debt Discount
WriteOffOfUnamortizedDebtDiscount
317953 usd
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
504925 usd
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
248550 shares
vism Convertible Notes Payable Principle Amount
ConvertibleNotesPayablePrincipleAmount
33950 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
39599 usd
vism Convertible Notes Payable Conversion Expense
ConvertibleNotesPayableConversionExpense
3500 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
77049 usd
us-gaap Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
0.31
CY2022Q4 vism Promissory Notes
PromissoryNotes
205000 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
vism Reverse Stock Split Outstanding Common Shares
ReverseStockSplitOutstandingCommonShares
3916144800 shares
vism Total Reverse Stock Split Outstanding Common Shares
TotalReverseStockSplitOutstandingCommonShares
2896396 shares
vism Description Of Reverse Stock Split Effect
DescriptionOfReverseStockSplitEffect
This action also reduced the number of authorized common shares of the Company from 10,000,000,000 to 1,000,000,000.
vism Description Of Warrant2 Year Life
DescriptionOfWarrant2YearLife
In January and February 2021, we issued 2,268 warrants with a two year life, and fixed exercise prices ranging from $7.425 to $27.00 per share.
CY2022Q4 vism Long Terms Debt Fair Value
LongTermsDebtFairValue
186972 usd
CY2022Q4 vism Warrant Exercisable
WarrantExercisable
69049 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
69049 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y4M20D
CY2022Q4 vism Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.37
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
69049 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.37
vism Plan Terminates Period
PlanTerminatesPeriod
P10Y
vism Options Issued For Purchase
OptionsIssuedForPurchase
11852 usd
CY2022Q4 us-gaap Share Price
SharePrice
20.25
vism Fair Value Of Shares
FairValueOfShares
0.00
vism Options To Purchase Vested Shares
OptionsToPurchaseVestedShares
2222 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
vism Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.0000 pure
CY2022 vism Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.0000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2222 shares
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
27.00
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
vism Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term Begining
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermBegining
P3Y3M29D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2222 shares
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
27.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y3M29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2222 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y3M29D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
27.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2222 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y3M29D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7407 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
7.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2305000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
40000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
772407 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.38
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1500000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.43
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
465000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y6M
vism Stock Based Compensation Expense
StockBasedCompensationExpense
291536 usd
CY2022Q4 us-gaap Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
67500 usd

Files In Submission

Name View Source Status
0001654954-23-001733-index-headers.html Edgar Link pending
0001654954-23-001733-index.html Edgar Link pending
0001654954-23-001733.txt Edgar Link pending
0001654954-23-001733-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vism-20221231.xsd Edgar Link pending
vism_10q.htm Edgar Link pending
vism_10qimg1.jpg Edgar Link pending
vism_ex311.htm Edgar Link pending
vism_ex312.htm Edgar Link pending
vism_ex321.htm Edgar Link pending
vism_ex322.htm Edgar Link pending
vism_10q_htm.xml Edgar Link completed
vism-20221231_lab.xml Edgar Link unprocessable
vism-20221231_def.xml Edgar Link unprocessable
vism-20221231_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
vism-20221231_pre.xml Edgar Link unprocessable